Connect Biopharma Holdings Limited is a biopharmaceutical company that focuses on developing immune modulators to treat autoimmune diseases and inflammation. Their lead product, CBP-201, is currently in Phase IIb clinical trial for inflammatory allergic diseases. Other products of the company, such as CBP-307, CBP-174, and CBP-233, are also in different stages of development to combat various inflammation illnesses.